Piriformis Injection

Evidence at a Glance

Piriformis injection treats piriformis syndrome - buttock pain, often with sciatic-type radiation, arising when the piriformis muscle irritates or compresses the sciatic nerve. Operationally it differs from a routine trigger point injection in three consequential ways: the piriformis is a deep muscle, so image guidance is clinically appropriate and separately reportable; the correct procedure code is a source of frequent error; and the diagnosis codes for piriformis syndrome are often absent from trigger-point coverage lists, creating denials even when the technique is flawless.

Domain	Summary
Medicare NCD	No national coverage determination specific to piriformis injection. Coverage flows through MAC trigger-point / therapeutic-injection LCDs and articles.
Medicare LCD / Article	Adjudicated under trigger-point injection policy when reported with 20552 (e.g., Novitas L35010 / A57751; First Coast A57702). Supported-diagnosis lists vary and may not include piriformis-syndrome codes - verify per MAC.
Commercial Coverage	Covered as medically necessary for piriformis syndrome refractory to conservative care (e.g., Cigna 0063 Local Injection Therapy; Aetna; UnitedHealthcare). Botulinum toxin injection is frequently considered investigational.
Evidence Level	Limited. Piriformis syndrome is a clinical, partly diagnosis-of-exclusion entity; image-guided injection improves accuracy, and botulinum toxin has modest RCT support for refractory cases.
Image Guidance	Appropriate and commonly required because the muscle is deep. Fluoroscopy (77002) or ultrasound (76942) is separately reportable; CT or MRI guidance is used selectively.
Prior Authorization	Anesthetic/steroid injection is usually not prior-authorized. Botulinum toxin chemodenervation of the piriformis typically requires prior authorization and drug-specific review.
Conservative Therapy	Document stretching, physical therapy (piriformis-directed), activity modification, and analgesics before injection to support medical necessity.
Diagnostic Block	A local-anesthetic piriformis block can serve a diagnostic role; a positive response supports the diagnosis and subsequent therapeutic injection.
Key Documentation	Buttock pain with sciatic-type features, provocative-test findings (e.g., FAIR position), exclusion of disc/radicular sources, guidance modality, injectate and units, and pre-/post pain scores.
Approval Considerations	Correct code (20552, not sciatic-nerve 64445), a payer-supported diagnosis, documented guidance, and adherence to frequency limits.

Procedure Overview

The piriformis is a deep external rotator of the hip that lies directly over the sciatic nerve as it exits the pelvis. In piriformis syndrome, spasm, hypertrophy, or anatomic variation of the muscle produces buttock pain that can radiate down the leg, mimicking lumbar radiculopathy. Piriformis injection delivers local anesthetic and/or corticosteroid (or, in refractory cases, botulinum toxin) into the muscle to relieve spasm and reduce sciatic-nerve irritation. Because the muscle sits deep beneath the gluteus maximus, accurate placement generally requires fluoroscopic, ultrasound, or occasionally CT guidance rather than palpation alone.

The operational profile therefore sits between a superficial trigger point injection and a formal image-guided spinal procedure. It borrows the procedure code and frequency logic of trigger point injection but adds legitimate image guidance, a more complex diagnosis-coding decision, and - for botulinum toxin - a genuine prior-authorization pathway. Getting paid consistently depends on aligning the code, the guidance documentation, and the diagnosis with each payer's

coverage list.

Relevant Anatomy (High-Level)

For coverage and coding purposes, the relevant anatomy is the piriformis muscle and its relationship to the sciatic nerve within the greater sciatic foramen. The piriformis originates on the anterior sacrum and inserts on the greater trochanter; the sciatic nerve typically passes just beneath (or, in anatomic variants, through) the muscle. This proximity explains both the sciatic-type symptoms of piriformis syndrome and the importance of image guidance to place the needle in the muscle belly while avoiding the nerve. The depth of the muscle beneath the gluteus maximus is the single anatomic fact that justifies image guidance as medically necessary, distinguishing this injection from a superficial trigger point injection.

Clinical Indications

Piriformis syndrome with buttock pain, with or without sciatic-type radiation, reproduced by provocative maneuvers (for example the FAIR - flexion, adduction, internal rotation - position).
Tenderness over the piriformis with a positive response to targeted examination.
Symptoms persisting despite a documented course of conservative therapy.
Exclusion of lumbar disc herniation, radiculopathy, and hip joint pathology as the primary pain generator, supported by history, examination, and imaging where indicated.
A diagnostic-anesthetic response supporting a piriformis source, when a diagnostic block has been performed.

Patient Selection

Because piriformis syndrome is partly a diagnosis of exclusion, selection quality determines both clinical benefit and coverage defensibility. Appropriate candidates demonstrate:

A consistent clinical picture of deep buttock pain with reproducible provocative findings rather than a purely radicular pattern.
Documented exclusion of competing sources (disc, facet, sacroiliac joint, hip).
Failure of, or contraindication to, conservative management.
Functional impairment the injection is intended to improve (sitting tolerance, gait, sleep).
For botulinum toxin candidates, refractoriness to prior anesthetic/steroid injection and conservative care, with realistic expectations.

Contraindications

Absolute	Relative
Overlying skin or soft-tissue infection.	Therapeutic anticoagulation or coagulopathy (individualized).
Known allergy to the planned injectate or contrast (if used).	Uncontrolled systemic infection or immunosuppression.
Patient refusal or inability to cooperate.	Pregnancy (agent, contrast, and radiation considerations).

For botulinum toxin: neuromuscular junction disorders (e.g., myasthenia gravis).

Medical Necessity

Medical necessity for piriformis injection rests on documenting a piriformis source of pain and the failure of less invasive care. The record should demonstrate:

A regional buttock pain complaint, with or without a sciatic-type referral pattern.
Provocative-test or examination findings localizing the pain to the piriformis.
Reasonable exclusion of lumbar radicular and hip sources.
A documented, failed course of conservative therapy or a contraindication to it.
The functional deficit being treated and the therapeutic goal.
The rationale for image guidance given the depth of the muscle.

Medicare Coverage Guidance

No National Coverage Determination addresses piriformis injection. When the service is reported with 20552, it is adjudicated under the applicable Medicare contractor's trigger-point injection LCD and companion article. The following principles apply:

Diagnosis coverage gap. Several MAC trigger-point policies do not list piriformis-syndrome diagnoses on their supported code lists, producing denials even when the injection is appropriate. Confirm which diagnoses your MAC accepts before submission.
Frequency limits. The same session limits that govern trigger point injection apply (commonly no more than three sessions per rolling 12 months, or documentation review beyond three sessions in three months, depending on MAC).
Single service per day. Report one unit of 20552 regardless of the number of needle passes.
Pain scales. Pre- and post-injection pain scores are expected in the record.
Image guidance. Fluoroscopic (77002) or ultrasound (76942) guidance is separately reportable when performed and documented, including a retained image and interpretation.
No anesthesia codes. Separate anesthesia codes are not billed with the injection.

Commercial Payer Comparison

Payer / Program	Typical Posture on Piriformis Injection
eviCore / Carelon / Cohere / Evolent	Anesthetic/steroid piriformis injection is generally not managed by interventional-pain UM programs. Botulinum toxin, where covered, is subject to specialty-drug review.
Cigna	Local Injection Therapy policy (0063) addresses muscle injections; covered for qualifying myofascial/piriformis presentations. Ultrasound guidance addressed separately (0139).
Aetna	Considers image-guided piriformis injection medically necessary for documented piriformis syndrome refractory to conservative care; botulinum toxin often considered experimental for this indication.
UnitedHealthcare	Covers under medical policy for qualifying piriformis syndrome; emphasizes exclusion of radicular sources and documented conservative care.
Humana	Medicare Advantage aligns with CMS/MAC trigger-point principles; commercial follows medical-necessity criteria with frequency edits.
Blue Cross Blue Shield plans	Plan-specific medical policies; verify local diagnosis and frequency criteria and any guidance-specific rules.

Documentation Requirements

Buttock pain complaint with radiation pattern described.
Provocative-test findings (e.g., FAIR position) documented.
Exclusion of lumbar radicular and hip sources noted.
Pre-injection numeric pain score.
Conservative treatment history or contraindication.
Image guidance modality (fluoroscopy / ultrasound / CT) and rationale.
Retained guidance image and interpretation on file.
Injectate name, concentration, and units (or toxin dose/units).
Laterality (right / left) clearly documented.
Post-injection pain score and immediate percent relief.
Functional impairment and therapeutic goal.
Signed and dated procedure note.

Imaging Requirements

Two imaging concepts must be distinguished. Diagnostic imaging (MRI of the lumbar spine or pelvis) is used in the work-up to exclude disc herniation, radiculopathy, and hip pathology before attributing symptoms to the piriformis. Procedural image guidance is used during the injection itself: fluoroscopy (77002), ultrasound (76942), or CT places the needle accurately in a deep muscle overlying the sciatic nerve. Procedural guidance is separately reportable when performed and documented with a retained image and interpretation. Ultrasound has the advantage of direct nerve visualization and no radiation; fluoroscopy with contrast confirms intramuscular spread. The choice should be documented and the medical necessity of guidance tied to the muscle's depth.

Prior Authorization Workflow

Benefit verification. Confirm coverage for the muscle injection, for the planned guidance code, and - critically - for botulinum toxin if that route is contemplated.
Diagnosis validation. Confirm the working diagnosis maps to a code the payer supports; anticipate that piriformis-syndrome codes may not appear on trigger-point LCD lists.
Authorization (toxin pathway). For botulinum toxin, submit a prior-authorization package documenting refractoriness, prior injection failure, and functional impairment, plus drug and units.
Clinical documentation. Capture provocative-test findings, exclusion of radicular sources, and pre-injection pain score.
Procedure and coding. Report 20552 with the appropriate guidance code; avoid the sciatic-nerve code 64445 and modifier 50.
Post-service integrity. Ensure the note carries laterality, guidance documentation, and pre-/post pain scores for audit resilience.

Common Prior Authorization & Claim Denials

Denial Reason	Root Cause / Prevention
Diagnosis not on covered list	Piriformis-syndrome code absent from the MAC trigger-point list. Verify supported diagnoses; document a covered, fully specified code the record substantiates.
Wrong procedure code	Sciatic-nerve injection 64445 billed for a muscle injection. Report 20552 for piriformis muscle injection per AMA guidance.
Guidance not supported / bundled	Guidance billed without a retained image, interpretation, or medical-necessity rationale, or reported when bundled. Document depth rationale and retain the image.
Frequency limit exceeded	Sessions beyond the payer limit. Track cumulative, patient-level injection history.
NCCI bundling with SI joint	20552 bundled into 27096 when performed with a sacroiliac injection. Append the appropriate modifier only when the services are genuinely distinct.
Botulinum toxin not authorized / investigational	Toxin billed without authorization or against an investigational policy. Obtain prior authorization and document refractoriness.
Missing pre/post pain scores	Record lacks documented pain scales. Capture numeric pre-/post scores.
Modifier 50 reported	Bilateral modifier appended to 20552. Do not use modifier 50 with this code.

Appeal Strategies

Submit the procedure note documenting provocative-test findings, exclusion of radicular sources, guidance modality with retained image, injectate/units, and pre-/post pain scores.
For diagnosis denials, confirm and, where appropriate, correct to a payer-supported, fully specified code the record substantiates.
For guidance denials, supply the retained image and interpretation and the depth rationale establishing that palpation guidance was insufficient.
For botulinum toxin denials, document failed anesthetic/steroid injection, failed conservative care, functional impairment, and any supportive literature.
For frequency denials, justify the clinical need for repeat injection and the response to prior sessions.
Cite the applicable LCD/article or commercial policy establishing that criteria were met.

Coding & Billing Overview

Applicable CPT® Codes

CPT®	Descriptor	Application
20552	Injection(s); single or multiple trigger point(s), 1 or 2 muscle(s)	Primary code for piriformis muscle injection (per AMA CPT® Assistant guidance).
20553	Injection(s); single or multiple trigger point(s), 3 or more muscle(s)	Only when 3+ muscles are injected; uncommon for isolated piriformis.
77002	Fluoroscopic guidance for needle placement	Separately reportable when fluoroscopy is used and documented.
76942	Ultrasonic guidance for needle placement, imaging S&I	Separately reportable when ultrasound is used; requires retained image.
64646	Chemodenervation of trunk muscle(s); 1-5 muscles	For botulinum toxin injection of the piriformis; coverage often restricted.

HCPCS (Injectate)

Corticosteroid injectate is reported with the appropriate J-code (for example J1030 methylprednisolone acetate 40 mg, or J3301 triamcinolone acetonide per 10 mg). For chemodenervation, botulinum toxin is reported per unit (for example J0585 onabotulinumtoxinA) and is subject to specialty-drug review. Local anesthetics are frequently not separately payable. Report the drug on the same claim as the injection.

Common ICD-10-CM Diagnosis Codes

Code	Description	Note
G57.00	Lesion of sciatic nerve, unspecified lower limb	Indexed synonym: piriformis syndrome; specify laterality where known.
G57.01	Lesion of sciatic nerve, right lower limb	Right piriformis syndrome.
G57.02	Lesion of sciatic nerve, left lower limb	Left piriformis syndrome.
M62.838	Other muscle spasm	Piriformis muscle spasm without nerve involvement.
M54.30-M54.32	Sciatica (by laterality)	Differential; use when radicular pain lacks a piriformis source.
M79.18	Myalgia, other site	Secondary/associated muscular pain.

Modifiers, POS & ASC

Element	Guidance
Modifier 25	For a significant, separately identifiable E/M on the same day.
Modifier 50	Not reported with 20552, even for bilateral injection.
Modifier 59 / X{EPSU}	Only to unbundle a genuinely distinct service (e.g., 20552 with 27096 when both are separately performed and documented).
Modifier RT / LT	Document laterality of the injected side.
Place of Service	POS 11 (office) or 24 (ASC) where guidance is performed; POS 22 for hospital outpatient.
NCCI note	20552 bundles into 27096 (sacroiliac joint injection); unbundle only when distinct and supported.

Clinical Documentation Checklist

Buttock pain and radiation pattern.
Provocative-test findings (e.g., FAIR).
Exclusion of radicular / hip sources.
Pre-injection numeric pain score.
Guidance modality and depth rationale.
Retained guidance image and interpretation.
Laterality (RT / LT).
Injectate name, concentration, units (or toxin dose).
Conservative care history / contraindication.
Post-injection pain score and percent relief.
Correct code (20552, not 64445) + guidance code.
Payer-supported diagnosis confirmed.

Procedure Comparison

Feature	Piriformis Injection	Superficial Trigger Point	Sciatic Nerve Block
Target	Deep piriformis muscle	Superficial skeletal muscle	Sciatic nerve
Typical CPT®	20552 (+77002 / 76942)	20552 / 20553	64445
Image guidance	Usually required (deep)	Usually none	Often used
Injectate	Anesthetic/steroid or toxin	Anesthetic/saline/steroid	Anesthetic +/- steroid
Prior auth	Usually none (toxin: yes)	Usually none	Varies
Coverage focus	Piriformis dx + guidance	Myofascial findings	Nerve pathology

GoHealthcare Clinical Insights

The diagnosis is the denial engine, not the technique. The most common avoidable piriformis-injection denial is a piriformis-syndrome diagnosis that is clinically correct but absent from the payer's supported list. Build a payer-by-payer diagnosis crosswalk so front-end staff know, before the visit, which code the plan will accept and what the record must support. Document the depth, earn the guidance. A single sentence establishing that the piriformis is deep to the gluteus maximus and not reliably reached by palpation converts image guidance from a denial risk into a defensible, separately payable service. Separate the two imaging conversations. Reviewers conflate diagnostic MRI with procedural guidance. Keep the exclusion work-up and the intra-procedural guidance clearly delineated in the record so each stands on its own necessity.

GoHealthcare Leadership Perspective

Piriformis injection is a small procedure that quietly touches three different operational systems: trigger-point frequency logic, image-guidance documentation, and - for botulinum toxin - specialty-drug prior authorization. Practices that treat it as a simple muscle injection tend to miss the guidance revenue on one end and absorb toxin denials on the other. The leadership priority is a decision pathway that routes each case correctly from the outset: anesthetic/steroid cases move through a light-touch documentation gate, while botulinum-toxin candidates are pulled into a full authorization workflow before scheduling. A payer diagnosis crosswalk and a guidance-documentation standard convert an error-prone service into a predictable one, and position the practice to defend it on audit.

GoHealthcare Prior Authorization Insight

The prior-authorization insight for piriformis injection is to triage by injectate. Anesthetic and steroid injections behave like trigger point injections: rarely authorized, but exposed to diagnosis and frequency edits and post-payment review. Botulinum toxin behaves like a specialty drug: prospectively authorized, frequently gated by an investigational-status policy, and dependent on a documented failure ladder. Our quality-assurance approach verifies the diagnosis against the payer's list first, confirms guidance documentation second, and - for toxin - assembles the refractoriness package before the patient is scheduled. This sequencing prevents the two failure modes that account for most piriformis-injection revenue loss: unsupported diagnoses and unauthorized toxin.

GoHealthcare Case Study

The following case is a composite created for education. It does not depict any actual patient or organization.

Clinical Scenario

A patient with persistent right buttock pain and sciatic-type radiation, unresponsive to physical therapy and analgesics, underwent ultrasound-guided right piriformis injection with anesthetic and corticosteroid. The practice billed 20552 and 76942 with a piriformis-syndrome diagnosis.

Documentation & Coding Challenges

The claim denied on two grounds: the reported diagnosis code was not on the contractor's trigger-point supported-diagnosis list, and the ultrasound guidance was billed without a retained image or interpretation in the submitted record. A prior claim for a different patient had used 64445 in error, compounding the practice's denial pattern.

Payer & Prior Authorization Barriers

Because the anesthetic/steroid injection required no prior authorization, no checkpoint had validated the diagnosis or the guidance documentation before submission, allowing both errors to reach the payer.

Resolution Strategy

The practice appealed with a corrected, payer-supported diagnosis the record substantiated, attached the retained ultrasound image and interpretation, and supplied the depth rationale for guidance. Prospectively, it built a payer diagnosis crosswalk, a mandatory guidance-image capture step, and an edit blocking 64445 on piriformis muscle-injection claims.

Outcome & Lessons Learned

The appeal was paid, and piriformis-injection denials fell over the following quarter. The lesson: for piriformis injection, revenue integrity depends on three front-end controls - the right code, a payer-supported diagnosis, and captured guidance documentation - none of which a prior-authorization requirement would have forced.

GoHealthcare Best Practices

Maintain a payer-by-payer diagnosis crosswalk for piriformis syndrome and confirm coverage before the visit.
Standardize capture and retention of the guidance image and interpretation on every image-guided injection.
Apply a claim edit that blocks 64445 on piriformis muscle-injection claims and blocks modifier 50 on 20552.
Route botulinum-toxin candidates into a full prior-authorization workflow before scheduling.
Document the depth rationale for guidance and the exclusion of radicular / hip sources.
Track cumulative injection frequency at the patient level.

Common Mistakes

Billing sciatic-nerve injection 64445 for a piriformis muscle injection.
Reporting guidance without a retained image or interpretation.
Submitting a piriformis-syndrome diagnosis not on the payer's supported list.
Using the non-billable myalgia parent M79.1, or mis-coding to G57.2 (femoral nerve).
Appending modifier 50 to 20552 for bilateral injection.
Billing botulinum toxin without prior authorization.
Failing to unbundle correctly when performed with a sacroiliac joint injection.
Omitting laterality or pre-/post pain scores.

Pearls and Pitfalls

Pearls	Pitfalls
Report 20552 for the muscle; reserve 64445 for true sciatic-nerve injection.	Substituting the nerve code to raise reimbursement.
Document depth to justify separately reportable guidance.	Billing guidance with no retained image or rationale.
Confirm the diagnosis is on the payer's list before the visit.	Assuming a clinically correct diagnosis is a covered one.
Triage botulinum-toxin cases into prior authorization early.	Treating toxin like a routine injectate.
Specify laterality on every claim.	Omitting RT/LT and inviting a specificity denial.

Frequently Asked Questions

What CPT code is used for a piriformis muscle injection?

20552 (trigger point injection, 1 or 2 muscles). Per AMA CPT® Assistant guidance, the sciatic-nerve code 64445 should not be used for a piriformis muscle injection.

When would 64445 ever apply?

Only when the sciatic nerve itself is injected - a different procedure. A muscle injection into the piriformis is not a sciatic nerve block.

Is image guidance appropriate for piriformis injection?

Yes. The piriformis is deep beneath the gluteus maximus and is not reliably reached by palpation, so fluoroscopic (77002) or ultrasound (76942) guidance is clinically appropriate and separately reportable when documented.

Why did my piriformis injection deny even though it was done correctly?

The most common cause is a diagnosis code not on the payer's trigger-point supported-diagnosis list. Verify supported diagnoses before submitting.

What is the correct ICD-10 code for piriformis syndrome?

Piriformis syndrome indexes to the sciatic-nerve lesion family G57.0- (G57.00 unspecified, G57.01 right, G57.02 left). M62.838 applies to piriformis muscle spasm without nerve involvement.

Is G57.2 a piriformis code?

No. G57.2 is a femoral-nerve lesion. Piriformis syndrome maps to G57.0-, not G57.2.

Can I bill both the injection and the guidance?

Yes, when guidance is performed and documented with a retained image and interpretation. Report 20552 with 77002 or 76942 as applicable.

Does piriformis injection require prior authorization?

Anesthetic/steroid injection usually does not. Botulinum toxin chemodenervation typically does, and is often subject to an investigational-status policy.

How is botulinum toxin injection of the piriformis coded?

Chemodenervation of trunk muscle(s), 1-5 muscles, is reported with 64646, plus the toxin drug code per unit (for example J0585). Coverage is frequently restricted.

Do trigger-point frequency limits apply?

Yes, when reported with 20552. The same session limits as trigger point injection apply, so track cumulative patient-level frequency.

Should modifier 50 be used for bilateral piriformis injection?

No. Modifier 50 is not used with 20552. Document laterality with RT/LT as appropriate.

What place of service applies?

POS 11 (office) or 24 (ASC) where guidance is performed, and POS 22 for hospital outpatient settings.

Is a diagnostic block required first?

Not universally, but a positive anesthetic response supports the piriformis diagnosis and can strengthen medical necessity for therapeutic injection.

What conservative care should precede injection?

Piriformis-directed stretching, physical therapy, activity modification, and analgesics; document the trial and its outcome.

How do I avoid confusing piriformis syndrome with radiculopathy?

Document provocative-test findings localizing to the piriformis and the exclusion of disc/radicular and hip sources through history, examination, and imaging.

Is ultrasound or fluoroscopy preferred?

Both are acceptable. Ultrasound avoids radiation and visualizes the nerve; fluoroscopy with contrast confirms intramuscular spread. Document the modality and rationale.

What happens if I bill 20552 with a sacroiliac injection?

NCCI bundles 20552 into 27096. Unbundle with an appropriate modifier only when the two services are genuinely distinct and documented.

Are pre- and post-injection pain scores required?

Yes. They are expected in the record and are central to demonstrating medical necessity and response.

Can fibromyalgia or generalized myalgia be the indication?

Only if it accurately reflects the clinical picture; a piriformis-specific presentation should be coded to the piriformis/sciatic-nerve family, not a generalized pain code.

What single control most reduces piriformis-injection denials?

A payer diagnosis crosswalk that confirms, before the visit, which piriformis diagnosis the plan accepts and what the record must support.

Is corticosteroid always included?

No. Some injections use anesthetic alone (including diagnostic blocks). Document the exact injectate and units used.

How should refractory cases be escalated?

After failed conservative care and failed anesthetic/steroid injection, consider botulinum toxin with prior authorization, or reassessment for alternative diagnoses.

Key Takeaways

Report the piriformis muscle injection with 20552 - never 64445 (sciatic nerve).
Image guidance (77002 or 76942) is appropriate and separately reportable because the muscle is deep; retain the image and interpretation.
Piriformis syndrome maps to G57.0- (not G57.2); M62.838 covers isolated muscle spasm; specify laterality.
Diagnosis-coverage gaps on trigger-point lists are the leading denial cause - verify supported codes per payer.
Botulinum toxin chemodenervation (64646) typically requires prior authorization and is often investigational.
Trigger-point frequency limits apply; track cumulative patient-level history.
Do not append modifier 50; unbundle correctly from sacroiliac injections.

Future Outlook

Ultrasound guidance is likely to become the dominant modality for piriformis injection as point-of-care musculoskeletal ultrasound proliferates, offering direct nerve visualization without radiation. Diagnostic precision may improve as imaging and electrodiagnostic criteria for piriformis syndrome are refined, which could gradually expand payer recognition of piriformis-specific diagnoses. Botulinum toxin's role will hinge on stronger comparative evidence; until then it will remain authorization-gated and frequently investigational. Practices that standardize diagnosis crosswalks and guidance documentation now will adapt readily as these criteria evolve.

References

American Medical Association. CPT® Assistant - Piriformis Muscle Injection Reporting (guidance that 20552, not 64445, is reported). https://www.ama-assn.org/practice-management/cpt KZA. Coding Coaches - Piriformis Muscle Injection (20552 with 76942). https://www.kzanow.com/coding-coaches/piriformis-muscle-injection Find-A-Code. Piriformis Injections coding overview (20552; 77002/76942 guidance). https://www.findacode.com/articles/piriformis-injections.html Centers for Medicare & Medicaid Services. LCD - Trigger Point Injections (L35010). https://www.cms.gov/medicare-coverage-database/view/lcd.aspx?LCDId=35010 Centers for Medicare & Medicaid Services. Billing and Coding: Trigger Point Injections (A57751). https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleID=57751 ICD-10-CM 2026, G57.00 - G57.02 (Lesion of sciatic nerve; piriformis syndrome). https://www.icd10data.com/ICD10CM/Codes/G00-G99/G50-G59/G57-ICD-10-CM 2026, M62.838 (Other muscle spasm; piriformis muscle spasm). https://www.icd10data.com/ICD10CM/Codes/M00-M99/M60-M63/M62-/M62.838 Cigna. Medical Coverage Policy 0063 - Local Injection Therapy. https://static.cigna.com/assets/chcp/pdf/coveragePolicies/medical/mm_0063_coveragepositioncriteria_local_injection_therapy.pdf Outsource Strategies. Coding Musculoskeletal Ultrasound-Guided Procedures (76942 with 20552). https://www.outsourcestrategies.com/resources/coding-musculoskeletal-ultrasound-guided-procedures/American Society of Interventional Pain Physicians (ASIPP). https://www.asipp.org American Association of Neuromuscular & Electrodiagnostic Medicine (AANEM). https://www.aanem.org

Reading Recommendations

AMA CPT® Assistant guidance on piriformis and trigger point injection reporting.
Your MAC's trigger-point LCD and Billing & Coding Article, including the supported-diagnosis list.
Commercial local-injection-therapy and botulinum-toxin medical policies for your top payers.
NCCI policy manual sections on injection and imaging-guidance bundling.

Recommended Downloads

Piriformis Injection Structured Procedure Note Template.
Payer Diagnosis Crosswalk Worksheet (piriformis syndrome).
Image-Guidance Documentation Checklist.
Botulinum Toxin Prior-Authorization Packet Template.

Visual Recommendations

High-level illustration of the piriformis muscle overlying the sciatic nerve.
Decision tree: buttock pain work-up to piriformis-injection candidacy.
Injectate-based triage map (anesthetic/steroid vs botulinum toxin pathways).
Coding matrix: 20552 plus guidance codes and modifiers.
Payer diagnosis-coverage comparison for piriformis syndrome.
Guidance-documentation checklist infographic.

Educational Disclaimer

This document is intended for educational and operational reference purposes only. It does not replace physician clinical judgment, payer policy review, legal advice, or official CMS guidance, and it is not a procedural or physician training manual. Coverage policies, coding guidance, frequency limitations, and reimbursement requirements change frequently and vary by payer, plan, and jurisdiction; all codes and coverage criteria must be independently verified against the applicable payer policy and current regulatory sources before submission. CPT® is a registered trademark of the American Medical Association. GoHealthcare Practice Solutions assumes no liability for actions taken in reliance on this educational material.

This webpage does not replace physician judgment, official payer policy, legal advice, or current coding guidance. CPT® is a registered trademark of the American Medical Association.